BACKGROUND: Interleukin (IL)-20 is a recently discovered cytokine displaying increased levels in psoriatic lesions. Interestingly, IL-20 levels decrease with antipsoriatic treatment, correlating with clinical improvement. However, the role of IL-20 in the aetiology of psoriasis is unknown. OBJECTIVES: In this study, we investigate the effects both of blocking IL-20 signalling in psoriatic plaques and of adding IL-20 to nonlesional psoriasis skin. METHODS: We employed the human skin xenograft transplantation model in which psoriatic plaques and nonlesional keratome skin biopsies obtained from donors with moderate to severe plaque psoriasis were transplanted on to immuno-deficient mice. The transplanted mice were treated with anti-IL-20 antibodies or recombinant human IL-20. RESULTS: We demonstrate that blocking IL-20 signalling with anti-IL-20 antibodies induces psoriasis resolution and inhibits psoriasis induction. We also demonstrate that continuous IL-20 infusion, together with injection of additional nonactivated leucocytes, promotes induction of psoriasis in nonlesional skin from patients with psoriasis. CONCLUSIONS: The results suggest that IL-20 plays a critical role in the induction and maintenance of psoriasis, and IL-20 is suggested as a new possible specific target in psoriasis treatment.
BACKGROUND:Interleukin (IL)-20 is a recently discovered cytokine displaying increased levels in psoriatic lesions. Interestingly, IL-20 levels decrease with antipsoriatic treatment, correlating with clinical improvement. However, the role of IL-20 in the aetiology of psoriasis is unknown. OBJECTIVES: In this study, we investigate the effects both of blocking IL-20 signalling in psoriatic plaques and of adding IL-20 to nonlesional psoriasis skin. METHODS: We employed the human skin xenograft transplantation model in which psoriatic plaques and nonlesional keratome skin biopsies obtained from donors with moderate to severe plaque psoriasis were transplanted on to immuno-deficient mice. The transplanted mice were treated with anti-IL-20 antibodies or recombinant humanIL-20. RESULTS: We demonstrate that blocking IL-20 signalling with anti-IL-20 antibodies induces psoriasis resolution and inhibits psoriasis induction. We also demonstrate that continuous IL-20 infusion, together with injection of additional nonactivated leucocytes, promotes induction of psoriasis in nonlesional skin from patients with psoriasis. CONCLUSIONS: The results suggest that IL-20 plays a critical role in the induction and maintenance of psoriasis, and IL-20 is suggested as a new possible specific target in psoriasis treatment.
Authors: Maria Jakobsen; Karin Stenderup; Cecilia Rosada; Brian Moldt; Søren Kamp; Tomas N Dam; Thomas G Jensen; Jacob Giehm Mikkelsen Journal: Mol Ther Date: 2009-06-30 Impact factor: 11.454
Authors: Naomi J Logsdon; Ashlesha Deshpande; Bethany D Harris; Kanagalaghatta R Rajashankar; Mark R Walter Journal: Proc Natl Acad Sci U S A Date: 2012-07-16 Impact factor: 11.205
Authors: Ulrik Ralfkiaer; Peter H Hagedorn; Nannie Bangsgaard; Marianne B Løvendorf; Charlotte B Ahler; Lars Svensson; Katharina L Kopp; Marie T Vennegaard; Britt Lauenborg; John R Zibert; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Rolf Søkilde; Lise M Gjerdrum; Tord Labuda; Anne-Merete Mathiesen; Kirsten Grønbæk; Mariusz A Wasik; Malgorzata Sokolowska-Wojdylo; Catherine Queille-Roussel; Robert Gniadecki; Elisabeth Ralfkiaer; Carsten Geisler; Thomas Litman; Anders Woetmann; Christian Glue; Mads A Røpke; Lone Skov; Niels Odum Journal: Blood Date: 2011-08-24 Impact factor: 22.113
Authors: Phillip J Finley; Cory E DeClue; Scott A Sell; Joseph M DeBartolo; Laurie P Shornick Journal: Adv Wound Care (New Rochelle) Date: 2016-11-01 Impact factor: 4.730
Authors: Maria Jakobsen; Anne Louise Askou; Karin Stenderup; Cecilia Rosada; Frederik Dagnæs-Hansen; Thomas G Jensen; Thomas J Corydon; Jacob Giehm Mikkelsen; Lars Aagaard Journal: Hum Gene Ther Methods Date: 2015-08 Impact factor: 2.396